| Interim report January – September 2022 | Report (pdf) |
| Promore Pharma Interim report January – June 2022 | Report (pdf) |
| Promore Pharma — interim report January-March 2022 | Report (pdf) |
| Interim report January – December 2021 | Report (pdf) |
The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.
To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.
To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.